Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pidotimod activity against chronic bronchitis exacerbations

A Ciaccia1

  • 1Department of Respiratory Tract Diseases and Physiology, University of Ferrara, Italy.

Arzneimittel-Forschung
|December 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Degree of control of physician-diagnosed asthma and COPD in Italy.

Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace·2007
Same author

Ectopic thymoma simulating a pericardial cyst.

Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace·2006
Same author

Asthma is not a common cause of severe chronic respiratory failure in non-smokers: ALOT study.

Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace·2005
Same author

Underuse of spirometry by general practitioners for the diagnosis of COPD in Italy.

Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace·2005
Same author

Mucin expression in peripheral airways of patients with chronic obstructive pulmonary disease.

Histopathology·2004
Same author

COPD increases the risk of squamous histological subtype in smokers who develop non-small cell lung carcinoma.

Thorax·2004
Same journal

Wirksamkeit und Verträglichkeit eines pflanzlichen Arzneimittels mit Kapuzinerkressenkraut und Meerrettich bei akuter Sinusitis, akuter Bronchitis und akuter Blasenentzündung im Vergleich zu anderen Therapien unter den Bedingungen der täglichen Praxis.

Arzneimittel-Forschung·2013
Same journal

Abstracts of the Paul-Martini-Stiftung Symposium 2012 in combination with the National Academy of Leopoldina. November 16-17, 2012. Berlin, Germany.

Arzneimittel-Forschung·2013
Same journal

Leave-one-out procedure in the validation of elimination rate constant analysis.

Arzneimittel-Forschung·2012
Same journal

Pharmacokinetic and myocardial enzyme profiles of two administration routes of epirubicin in breast cancer patients.

Arzneimittel-Forschung·2012
Same journal

Synthesis, anti-hypertensive effect of a novel angiotensin II AT1 receptor antagonist and its anti-tumor activity in prostate cancer.

Arzneimittel-Forschung·2012
Same journal

Effect of zeolite nano-materials and artichoke (Cynara scolymus L.) leaf extract on increase in urinary clearance of systematically absorbed nicotine.

Arzneimittel-Forschung·2012
See all related articles

Pidotimod significantly reduced infectious exacerbations in chronic bronchitis patients, leading to fewer episodes and less antibiotic use. This immunomodulator demonstrated good tolerability over a 5-month study period.

Area of Science:

  • Immunology
  • Pharmacology
  • Respiratory Medicine

Background:

  • Chronic bronchitis (CB) frequently involves infectious exacerbations, impacting patient quality of life and healthcare costs.
  • Current management strategies for CB exacerbations often rely on antibiotics, raising concerns about resistance and side effects.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of pidotimod in managing infectious exacerbations of chronic bronchitis.
  • To compare pidotimod's effects against a placebo in a controlled clinical trial setting.

Main Methods:

  • A 5-month, double-blind, placebo-controlled study involving 580 patients with chronic bronchitis.
  • Patients received either pidotimod or placebo, with 60 days of treatment and 90 days of follow-up.
  • Outcomes measured included frequency and duration of infectious episodes, antibiotic use, and days of reduced activity.

Related Experiment Videos

Main Results:

  • The pidotimod group experienced fewer and shorter infectious episodes compared to placebo.
  • Patients receiving pidotimod required fewer days of antibiotic therapy and had fewer days unable to perform normal activities.
  • Significant benefits were observed during the follow-up period, and in less severe cases, also during treatment.

Conclusions:

  • Pidotimod is effective in reducing the burden of infectious exacerbations in chronic bronchitis patients.
  • The immunomodulator pidotimod offers a well-tolerated therapeutic option for managing CB exacerbations.
  • These findings support pidotimod's role in improving clinical outcomes for chronic bronchitis patients.